etaracizumab

BIOLOGICAL3 trials

Sponsors

Memorial Sloan Kettering Cancer Center, University of Wisconsin, Madison, National Cancer Institute (NCI)

Conditions

Colorectal CancerLymphomaRecurrent Renal Cell CancerRenal Cell CarcinomaSmall Intestine CancerStage III Renal Cell CancerStage IV Renal Cell CancerUnspecified Adult Solid Tumor, Protocol Specific

Phase 1

Monoclonal Antibody Therapy in Treating Patients With Refractory Advanced Solid Tumors or Lymphoma

CompletedNCT00049712

University of Wisconsin, MadisonLymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific

Start: 2002-10-31End: 2006-02-28Updated: 2019-12-13

Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer

CompletedNCT00027729

Memorial Sloan Kettering Cancer CenterColorectal Cancer

Start: 2001-06-30End: 2004-11-30Updated: 2013-06-05

Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer

TerminatedNCT00684996

National Cancer Institute (NCI)Recurrent Renal Cell Cancer, Renal Cell Carcinoma, Stage III Renal Cell Cancer +1

Start: 2008-06-30End: 2010-10-31Updated: 2014-05-15